Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Cancer Diagnosis & Prognosis|January 5, 2026
Comparison of IO-IO and IO-TKI Treatment Outcomes in Metastatic Renal Cell Carcinoma: Influence of Metastatic Site CountHiroshi Kikuchi, Takahiro Osawa, Sei Naito, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|May 7, 2025
Association Between Overactive Bladder and Sarcopenia in Older Adults: A Population-Based Cohort StudySuguru Ito, Mayu Yagi, Kaori Sakurada, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|November 26, 2025
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE StudyTomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|March 17, 2026
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE StudyShuzo Hamamoto, Masahiro Nozawa, Suguru Shirotake, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|April 24, 2025
The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study)Koshiro Nishimoto, Go Kimura, Tomokazu Sazuka, et al.Current Urology|July 19, 2019
Risk of SOFA Deterioration in Conservative Treatment for Emphysematous Pyelonephritis: Pitfalls of Current Trends in Therapeutics from Multicenter Clinical ExperienceMichinobu Ozawa, Osamu Ichiyanagi, Suguru Fujita, et al.Journal of Clinical Monitoring and Computing|December 6, 2005
Scientific Grid activities and PKI deployment in the Cybermedia Center, Osaka UniversityToyokazu Akiyama, Yuuichi Teranishi, Kazunori Nozaki, et al.International Journal of Clinical Oncology|May 26, 2024
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapyKazuyuki Numakura, Yuya Sekine, Takahiro Osawa, et al.Scientific Reports|October 31, 2019
Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinomaSei Naito, Osamu Ichiyanagi, Tomoyuki Kato, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|March 25, 2020
New prognostic model for synchronous metastatic renal cell carcinomaSei Naito, Tomoyuki Kato, Osamu Ichiyanagi, et al.Pageof 10